Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence